Good morning :)
$
₹
Lexaria Bioscience Corp

Lexaria Bioscience Corp

LEXX

NASDAQ
Asset Logo

Lexaria Bioscience Corp

LEXX

NASDAQ
$14.2415.58% (+1.92)
$
₹
$14.2415.58% (+1.92)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Biotechnology

Micro Cap

With a market cap of $21.8M the stock is ranked 5442

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

4.35
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-5.38
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast
Analyst Ratings & Forecast

Based on 2 analysts' reports

Buy
2 analysts
Hold
0 analyst
Sell
0 analyst

Analysts expect a +271.02% price upside over the next year

Current Price$14.24
Target Price$52.5

Company Profile

Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. Its DehydraTECH is used with a range of active molecules, including glucagon-like peptide-1 drugs (GLP-1) and glucose -dependent insulinotropic polypeptide drugs (GIP), vitamins, pain medications, hormones, phosphodiesterase type 5 (PDE5) inhibitors, antivirals, nicotine and its analogs, and cannabinoids. The company's DehydraTECH technology is applied to various therapeutic indications, such as diabetes, weight loss, hypertension, epilepsy, and heart disease; is implemented in a multitude of ingestible or topically administered product formats comprising oral suspensions, tablets, capsules, foods, beverages, and oral products; and is suitable for a variety of product formats, including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. Its DehydraTECH is used with a range of active molecules, including glucagon-like peptide-1 drugs (GLP-1) and glucose -dependent insulinotropic polypeptide drugs (GIP), vitamins, pain medications, hormones, phosphodiesterase type 5 (PDE5) inhibitors, antivirals, nicotine and its analogs, and cannabinoids. The company's DehydraTECH technology is applied to various therapeutic indications, such as diabetes, weight loss, hypertension, epilepsy, and heart disease; is implemented in a multitude of ingestible or topically administered product formats comprising oral suspensions, tablets, capsules, foods, beverages, and oral products; and is suitable for a variety of product formats, including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

Peers

Peers

AbbVie Inc
ABBV
AbbVie Inc
—
—
P/E Ratio
73.51
73.51
—
—
1Y Return
23.04%
23.04%
Buy Reco %
57.14
57.14
Amgen Inc
AMGN
Amgen Inc
—
—
P/E Ratio
27.25
27.25
—
—
1Y Return
57.21%
57.21%
Buy Reco %
46.87
46.87
Gilead Sciences Inc
GILD
Gilead Sciences Inc
—
—
P/E Ratio
—
—
—
—
1Y Return
34.82%
34.82%
Buy Reco %
63.33
63.33
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
—
—
P/E Ratio
31.85
31.85
—
—
1Y Return
37.58%
37.58%
Buy Reco %
52.94
52.94
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
—
—
P/E Ratio
20.36
20.36
—
—
1Y Return
46.1%
46.1%
Buy Reco %
76.00
76.00

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Lexaria Bioscience Corp -4.35-
AbbVie Inc73.5150.450.36
Amgen Inc27.2520.262.10

Price Comparison

Price Comparison

1 Month

1 Year

5 Years

Loading...

Financials

Financials

Income

Balance Sheet

Cash Flow

0.1
-2.6
-1.5
0
-1.4
-1.9
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue0.140.080.080.180.170.170.1700.020
Net Income-0.64-1.78-2.18-2.70-2.71-3.78-2.69-1.59-1.44-1.99
Net Profit Margin-447.95%-2121.06%-2600.94%-1470.01%-1559.31%-2177.63%-1549.33%--7249.89%-
See CostsAll values in $ Million

Frequently asked questions

Frequently asked questions

  1. Lexaria Bioscience Corp (LEXX) share price today is $14.24 as of September 5, 2026 at 1:30 AM IST. The stock touched a day high of $14.24 and a day low of $12.11.

  2. Lexaria Bioscience Corp stock trades on NASDAQ under the ticker symbol LEXX.

  3. Lexaria Bioscience Corp's market capitalization is $21.82M as of September 5, 2026 at 1:30 AM IST.

  4. Lexaria Bioscience Corp's price-to-earnings (P/E) ratio is N/A as of September 4, 2026.

  5. Lexaria Bioscience Corp's price-to-book (P/B) ratio is 4.35 as of September 4, 2026.

  6. Yes, You can buy Lexaria Bioscience Corp shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Lexaria Bioscience Corp shares in three steps: 1. Search Lexaria Bioscience Corp on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Lexaria Bioscience Corp trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Lexaria Bioscience Corp (LEXX) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.7022 shares at the current price of $14.24.

Loading...